Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically...

Related Keywords

,Amit Etkin ,Alto Neuroscience Inc ,Exchange Commission ,Alto Neuroscience ,Precision Psychiatry Platform ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,